149 related articles for article (PubMed ID: 31908003)
1. MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients.
Bao Y; Wei M; Ji X
J Clin Lab Anal; 2020 May; 34(5):e23168. PubMed ID: 31908003
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma.
Yu H; Peng S; Chen X; Han S; Luo J
J Clin Lab Anal; 2020 Sep; 34(9):e23399. PubMed ID: 32608537
[TBL] [Abstract][Full Text] [Related]
3. The Correlation of miR-671-5p with Diagnosis and Prognosis in Multiple Myeloma.
Yu K; Li J; Chen D; Huan W
Clin Lab; 2023 Aug; 69(8):. PubMed ID: 37560870
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
Yin Y; Yang W; Zhang L; Liu K; Luo Z
Hematology; 2021 Dec; 26(1):160-169. PubMed ID: 33528317
[TBL] [Abstract][Full Text] [Related]
5. Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients.
Xiang Y; Xu X; Yang B; Wu Z; Jiang R; Xie Y
Ir J Med Sci; 2022 Apr; 191(2):671-679. PubMed ID: 33864191
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-146b correlates with decreased acute respiratory distress syndrome risk, reduced disease severity, and lower 28-day mortality in sepsis patients.
Chen W; Liu L; Yang J; Wang Y
J Clin Lab Anal; 2020 Dec; 34(12):e23510. PubMed ID: 32845540
[TBL] [Abstract][Full Text] [Related]
7. Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma.
Wang W; Xie Y; Han X; Liu Y; Li P
Technol Cancer Res Treat; 2020; 19():1533033820935856. PubMed ID: 32799782
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
[TBL] [Abstract][Full Text] [Related]
9. Correlation of microRNA-146a/b with disease risk, biochemical indices, inflammatory cytokines, overall disease severity, and prognosis of sepsis.
Chen L; Yu L; Zhang R; Zhu L; Shen W
Medicine (Baltimore); 2020 May; 99(22):e19754. PubMed ID: 32481361
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNA-146a and microRNA-146b exhibit potential to serve as markers for acute pancreatitis management and prognosis.
Li XY; Wang YF; Li N
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12770-12780. PubMed ID: 33378026
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
[TBL] [Abstract][Full Text] [Related]
12. Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p.
Liu H; Wu Y; Wang S; Jiang J; Zhang C; Jiang Y; Wang X; Hong L; Huang H
BMC Cancer; 2019 Oct; 19(1):937. PubMed ID: 31601173
[TBL] [Abstract][Full Text] [Related]
13. Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients.
Zhou F; Guo L
Hematology; 2022 Dec; 27(1):596-602. PubMed ID: 35617291
[TBL] [Abstract][Full Text] [Related]
14. Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients.
Zhao P; Zhao X
J Clin Lab Anal; 2021 Nov; 35(11):e23924. PubMed ID: 34564896
[TBL] [Abstract][Full Text] [Related]
15. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
Li Y; Gong J; Zhang L
J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
[TBL] [Abstract][Full Text] [Related]
16. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition.
Xiang P; Yeung YT; Wang J; Wu Q; Du R; Huang C; Jia X; Gao Y; Zhi Y; Guo F; Wei H; Zhang D; Liu Y; Liu L; Liang L; Wang J; Song Y; Liu K; Fang B
Int J Cancer; 2021 Jun; 148(12):3071-3085. PubMed ID: 33609405
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.
Gupta N; Kumar R; Seth T; Garg B; Sati HC; Sharma A
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1601-1611. PubMed ID: 30891618
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma.
Shen X; Ye Y; Qi J; Shi W; Wu X; Ni H; Cong H; Ju S
Clin Chem Lab Med; 2017 May; 55(5):748-754. PubMed ID: 27155004
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients.
Shen H; Wang D; Zhan M; Ding H; Zhao H
J Clin Lab Anal; 2022 Feb; 36(2):e24198. PubMed ID: 34952998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
